AKBA (Akebia Therapeutics) חוב לטווח קצר להון

This daily price chart for Akebia Therapeutics (AKBA) on the GURU.Markets platform demonstrates the 2.04 metric, while the company's business relies on developing kidney therapies. High barriers to entry exist due to stringent FDA oversight and costly research and development. Operational efficiency is maintained by outsourcing delivery to third-party operators, ensuring a stable supply of specialized medications to medical centers.

Liquidity is critical for Akebia Therapeutics (AKBA) to maintain its operational activities as the company focuses on the commercialization of renal failure therapies. This metric compares obligations maturing within one year against equity, determining the extent of the business's reliance on rapid debt financing. By analyzing the short-term debt to equity ratio chart, an investor can assess the default risk and the stability of the company's capital structure.